These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 31233524)

  • 1. Impact of geographic origin on access to therapy and therapy outcomes in the Swiss Hepatitis C Cohort Study.
    Brezzi M; Bertisch B; Roelens M; Moradpour D; Terziroli Beretta-Piccoli B; Semmo N; Müllhaupt B; Semela D; Negro F; Keiser O;
    PLoS One; 2019; 14(6):e0218706. PubMed ID: 31233524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics of Foreign-Born Persons in the Swiss Hepatitis C Cohort Study: Implications for Screening Recommendations.
    Bertisch B; Giudici F; Negro F; Moradpour D; Müllhaupt B; Moriggia A; Estill J; Keiser O;
    PLoS One; 2016; 11(5):e0155464. PubMed ID: 27227332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Access to therapy and therapy outcomes in the Swiss Hepatitis C Cohort Study: a person-centred approach.
    Giudici F; Bertisch B; Negro F; Stirnimann G; Müllhaupt B; Moradpour D; Cerny A; Keiser O;
    J Viral Hepat; 2016 Sep; 23(9):697-707. PubMed ID: 27006320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis C Virus Infection Outcomes Among Immigrants to Canada: A Retrospective Cohort Analysis.
    Cooper CL; Thavorn K; Damian E; Corsi DJ
    Ann Hepatol; 2017; 16(5):720-726. PubMed ID: 28809741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term trends in hepatitis C prevalence, treatment uptake and liver-related events in the Swiss HIV Cohort Study.
    Baumann L; Braun DL; Cavassini M; Stoeckle M; Bernasconi E; Schmid P; Calmy A; Haerry D; Béguelin C; Fux CA; Wandeler G; Surial B; Rauch A
    Liver Int; 2024 Jan; 44(1):169-179. PubMed ID: 37850685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis C Infection and the Risk of Non-Liver-Related Morbidity and Mortality in HIV-Infected Persons in the Swiss HIV Cohort Study.
    Kovari H; Rauch A; Kouyos R; Rougemont M; Cavassini M; Schmid P; Stöckle M; Bernasconi E; Weber R; Ledergerber B;
    Clin Infect Dis; 2017 Feb; 64(4):490-497. PubMed ID: 28172403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decentralised hepatitis C testing and treatment in rural Cambodia: evaluation of a simplified service model integrated in an existing public health system.
    Zhang M; O'Keefe D; Craig J; Samley K; Bunreth V; Jolivet P; Balkan S; Marquardt T; Dousset JP; Le Paih M
    Lancet Gastroenterol Hepatol; 2021 May; 6(5):371-380. PubMed ID: 33743883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NIH Consensus Statement on Management of Hepatitis C: 2002.
    NIH Consens State Sci Statements; 2002 Jun 10-12; 19(3):1-46. PubMed ID: 14768714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-positive men who have sex with men are at high risk of development of significant liver fibrosis after an episode of acute hepatitis C.
    Steininger K; Boyd A; Dupke S; Krznaric I; Carganico A; Munteanu M; Neifer S; Schuetze M; Obermeier M; Arasteh K; Baumgarten A; Ingiliz P
    J Viral Hepat; 2017 Oct; 24(10):832-839. PubMed ID: 28439936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic review.
    Alberts CJ; Clifford GM; Georges D; Negro F; Lesi OA; Hutin YJ; de Martel C
    Lancet Gastroenterol Hepatol; 2022 Aug; 7(8):724-735. PubMed ID: 35576953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct-acting antiviral treatment for hepatitis C, reinfection and mortality among people attending an inner-city community health centre in Victoria, Canada.
    Selfridge M; Cunningham EB; Milne R; Drost A; Barnett T; Lundgren K; Guarasci K; Grebely J; Fraser C
    Int J Drug Policy; 2019 Oct; 72():106-113. PubMed ID: 31178254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. All-oral Direct-acting Antiviral Regimens in HIV/Hepatitis C Virus-coinfected Patients With Cirrhosis Are Efficient and Safe: Real-life Results From the Prospective ANRS CO13-HEPAVIH Cohort.
    Sogni P; Gilbert C; Lacombe K; Piroth L; Rosenthal E; Miailhes P; Gervais A; Esterle L; Chas J; Poizot-Martin I; Dominguez S; Simon A; Morlat P; Neau D; Zucman D; Bouchaud O; Lascoux-Combe C; Bani-Sadr F; Alric L; Goujard C; Vittecoq D; Billaud E; Aumaître H; Boué F; Valantin MA; Dabis F; Salmon D; Wittkop L
    Clin Infect Dis; 2016 Sep; 63(6):763-770. PubMed ID: 27317796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial.
    Andrieux-Meyer I; Tan SS; Thanprasertsuk S; Salvadori N; Menétrey C; Simon F; Cressey TR; Said HRHM; Hassan MRA; Omar H; Tee HP; Chan WK; Kumar S; Thongsawat S; Thetket K; Avihingsanon A; Khemnark S; Yerly S; Ngo-Giang-Huong N; Siva S; Swanson A; Goyal V; Bompart F; Pécoul B; Murad S
    Lancet Gastroenterol Hepatol; 2021 Jun; 6(6):448-458. PubMed ID: 33865507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low hepatitis C virus reinfection rate despite ongoing risk following universal access to direct-acting antiviral therapy among people living with HIV.
    Hosseini-Hooshyar S; Martinello M; Yee J; Read P; Baker D; Post JJ; Finlayson R; Bloch M; Doyle JS; Shaw D; Hellard M; Petoumenos K; Carson J; Dore GJ; Matthews GV;
    AIDS; 2020 Jul; 34(9):1347-1358. PubMed ID: 32590433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver function following hepatitis C virus eradication by direct acting antivirals in patients with liver cirrhosis: data from the PITER cohort.
    Quaranta MG; Ferrigno L; Tata X; D'Angelo F; Coppola C; Ciancio A; Bruno SR; Loi M; Giorgini A; Margotti M; Cossiga V; Brancaccio G; Dallio M; De Siena M; Cannizzaro M; Cavalletto L; Massari M; Mazzitelli M; De Leo P; Laccabue D; Baiocchi L; Kondili LA
    BMC Infect Dis; 2021 May; 21(1):413. PubMed ID: 33947337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rates of sustained virological response 12 weeks after the scheduled end of direct-acting antiviral (DAA)-based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy?
    Bischoff J; Mauss S; Cordes C; Lutz T; Scholten S; Moll A; Jäger H; Cornberg M; Manns MP; Baumgarten A; Rockstroh JK
    HIV Med; 2018 Apr; 19(4):299-307. PubMed ID: 29368456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Previous incarceration impacts access to hepatitis C virus (HCV) treatment among HIV-HCV co-infected patients in Canada.
    Kronfli N; Nitulescu R; Cox J; Moodie EE; Wong A; Cooper C; Gill J; Walmsley S; Martel-Laferrière V; Hull MW; Klein MB;
    J Int AIDS Soc; 2018 Nov; 21(11):e25197. PubMed ID: 30460791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of hospitalization for infection among patients with hepatitis B or C virus infection without cirrhosis in Taiwan: A cohort study.
    Lee YC; Wang JL; Dong YH; Chen HC; Wu LC; Chang CH
    PLoS Med; 2019 Sep; 16(9):e1002894. PubMed ID: 31518344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of direct-acting antivirals for HCV on mortality in a large population-based cohort study.
    Janjua NZ; Wong S; Abdia Y; Jeong D; Buller-Taylor T; Adu PA; Samji H; Wilton J; Pearce M; Butt ZA; Yu A; Binka M; Bartlett S; Alvarez M; Krajden M
    J Hepatol; 2021 Nov; 75(5):1049-1057. PubMed ID: 34097994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002.
    Seeff LB; Hoofnagle JH
    Clin Liver Dis; 2003 Feb; 7(1):261-87. PubMed ID: 12691470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.